The DOI matches its Crossref record; 641 of the 641 references it cites were found in a registry or an index.
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Open accessAbstract
Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% of liver cancer cases and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) and C (HCV), and metabolic disorders. There are no obvious symptoms in the early stage of HCC, which often leads to delays in diagnosis. Therefore, HCC patients usually present with tumors in advanced and incurable stages. Several signaling pathways are dis-regulated in HCC and cause uncontrolled cell propagation, metastasis, and recurrence of HCC. Beyond the frequently altered and therapeutically targeted receptor tyrosine kinase (RTK) pathways in HCC, pathways involved in cell differentiation, telomere regulation, epigenetic modification and stress response also provide therapeutic potential. Investigating the key signaling pathways and their inhibitors is pivotal for achieving therapeutic advancements in the management of HCC. At present, the primary therapeutic approaches for advanced HCC are tyrosine kinase inhibitors (TKI), immune checkpoint inhibitors (ICI), and combination regimens. New trials are investigating combination therapies involving ICIs and TKIs or anti-VEGF (endothelial growth factor) therapies, as well as combinations of two immunotherapy regimens. The outcomes of these trials are expected to revolutionize HCC management across all stages. Here, we provide here a comprehensive review of cellular signaling pathways, their therapeutic potential, evidence derived from late-stage clinical trials in HCC and discuss the concepts underlying earlier clinical trials, biomarker identification, and the development of more effective therapeutics for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–400 of 641
Qin, S., Li, Q., Gu, S., Chen, X., Lin, L., Wang, Z., Xu, A., Chen, X., Zhou, C., Ren, Z., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00109-6 · Cited by 252
Yarchoan, M., Gane, E. J., Marron, T. U., Perales-Linares, R., Yan, J., Cooch, N., Shu, D. H., Fertig, E. J., Kagohara, L. T., Bartha, G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02894-y · Cited by 250
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression
Fitamant, J., Kottakis, F., Benhamouche, S., Tian, H. S., Chuvin, N., Parachoniak, C. A., Nagle, J. M., Perera, R. M., Lapouge, M., Deshpande, V., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.027 · Cited by 248
Kelley, R. K., Gane, E., Assenat, E., Siebler, J., Galle, P. R., Merle, P., Hourmand, I. O., Cleverly, A., Zhao, Y., Gueorguieva, I., et al. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000056 · Cited by 247
Hedgehog signaling in tissue homeostasis, cancers and targeted therapies
Jing, J., Wu, Z., Wang, J., Luo, G., Lin, H., Fan, Y., & Zhou, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01559-5 · Cited by 247
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Q., Han, J., Yang, Y., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070961 · Cited by 246
Li, D., Liu, X., Lin, L., Hou, J., Li, N., Wang, C., Wang, P., Zhang, Q., Zhang, P., Zhou, W., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.270561 · Cited by 245
Reilley, M. J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 245
Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis
Kim, W., Khan, S. K., Gvozdenovic-Jeremic, J., Kim, Y., Dahlman, J., Kim, H., Park, O., Ishitani, T., Jho, E.-H., Gao, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88486 · Cited by 244
Activation of the hedgehog pathway in human hepatocellular carcinomas
Huang, S., He, J., Zhang, X., Bian, Y., Yang, L., Xie, G., Zhang, K., Tang, W., Stelter, A. A., Wang, Q., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi378 · Cited by 244
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
Cai, J., Wang, D., Zhang, G., & Guo, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221340 · Cited by 241
The role of telomeres and telomerase in cirrhosis and liver cancer
Nault, J.-C., Ningarhari, M., Rebouissou, S., & Zucman-Rossi, J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0165-3 · Cited by 239
Cancer epigenetics in clinical practice
Davalos, V., & Esteller, M. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21765 · Cited by 237
The Contribution of Epigenetics to Cancer Immunotherapy
Villanueva, L., Álvarez-Errico, D., & Esteller, M. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.002 · Cited by 235
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Fu, J., Su, X., Li, Z., Deng, L., Liu, X., Feng, X., & Peng, J. (2021) · Oncogene · doi:10.1038/s41388-021-01863-w · Cited by 235
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Lu, C., Redd, P. S., Lee, J. R., Savage, N., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 230
Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., & Okamoto, E. (1997) · Hepatology · doi:10.1002/hep.510250413 · Cited by 226
A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes
Gotzmann, J., Fischer, A. N. M., Zojer, M., Mikula, M., Proell, V, Huber, H., Jechlinger, M., Waerner, T., Weith, A., Beug, H., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209083 · Cited by 223
Kong, F.-H., Ye, Q.-F., Miao, X.-Y., Liu, X., Huang, S.-Q., Xiong, L., Wen, Y., & Zhang, Z.-J. (2021) · Theranostics · doi:10.7150/thno.54822 · Cited by 220
Ma, H.-Y., Yamamoto, G., Xu, J., Liu, X., Karin, D., Kim, J. Y., Alexandrov, L. B., Koyama, Y., Nishio, T., Benner, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.016 · Cited by 216
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
French, D. M., Lin, B. C., Wang, M., Adams, C., Shek, T., Hötzel, K., Bolon, B., Ferrando, R., Blackmore, C., Schroeder, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036713 · Cited by 216
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway
Viatour, P., Ehmer, U., Saddic, L. A., Dorrell, C., Andersen, J. B., Lin, C., Zmoos, A.-F., Mazur, P. K., Schaffer, B. E., Ostermeier, A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110198 · Cited by 214
Buurman, R., Gürlevik, E., Schäffer, V., Eilers, M., Sandbothe, M., Kreipe, H., Wilkens, L., Schlegelberger, B., Kühnel, F., & Skawran, B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.033 · Cited by 211
Bidkhori, G., Benfeitas, R., Klevstig, M., Zhang, C., Nielsen, J., Uhlen, M., Boren, J., & Mardinoglu, A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807305115 · Cited by 211
Yamada, T., De Souza, A. T., Finkelstein, S., & Jirtle, R. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10351 · Cited by 208
Hippo signalling in the liver: role in development, regeneration and disease
Russell, J. O., & Camargo, F. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00571-w · Cited by 207
Tovar, V., Cornella, H., Moeini, A., Vidal, S., Hoshida, Y., Sia, D., Peix, J., Cabellos, L., Alsinet, C., Torrecilla, S., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-309501 · Cited by 206
Lachenmayer, A., Toffanin, S., Cabellos, L., Alsinet, C., Hoshida, Y., Villanueva, A., Minguez, B., Tsai, H.-W., Ward, S. C., Thung, S., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.009 · Cited by 205
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Eghtedar, A., Verstovsek, S., Estrov, Z., Burger, J., Cortes, J., Bivins, C., Faderl, S., Ferrajoli, A., Borthakur, G., George, S., et al. (2012) · Blood · doi:10.1182/blood-2011-12-400051 · Cited by 200
Kazlauskas, A. (2017) · Gene · doi:10.1016/j.gene.2017.03.003 · Cited by 200
Yeo, W., Chung, H. C., Chan, S. L., Wang, L. Z., Lim, R., Picus, J., Boyer, M., Mo, F. K. F., Koh, J., Rha, S. Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2395 · Cited by 199
Niu, L., Liu, L., Yang, S., Ren, J., Lai, P. B. S., & Chen, G. G. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.002 · Cited by 198
Hepatocellular Carcinoma Immunotherapy
Sperandio, R. C., Pestana, R. C., Miyamura, B. V., & Kaseb, A. O. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-021121 · Cited by 198
METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma
Huang, M., Long, J., Yao, Z., Zhao, Y., Zhao, Y., Liao, J., Lei, K., Xiao, H., Dai, Z., Peng, S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0963 · Cited by 197
Lee, D.-H., Park, J. O., Kim, T.-S., Kim, S.-K., Kim, T.-H., Kim, M.-C., Park, G. S., Kim, J.-H., Kuninaka, S., Olson, E. N., et al. (2016) · Nature Communications · doi:10.1038/ncomms11961 · Cited by 196
Tornesello, M. L., Buonaguro, L., Tatangelo, F., Botti, G., Izzo, F., & Buonaguro, F. M. (2013) · Genomics · doi:10.1016/j.ygeno.2013.04.001 · Cited by 196
Cellular and molecular mechanisms of Hedgehog signalling
Zhang, Y., & Beachy, P. A. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00591-1 · Cited by 196
Hou, J., Zhang, H., Sun, B., & Karin, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.014 · Cited by 193
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 190
Hu, B., Zou, T., Qin, W., Shen, X., Su, Y., Li, J., Chen, Y., Zhang, Z., Sun, H., Zheng, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4140 · Cited by 184
Self-citationFGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation
Wu, X., Ge, H., Lemon, B., Vonderfecht, S., Weiszmann, J., Hecht, R., Gupte, J., Hager, T., Wang, Z., Lindberg, R., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.068783 · Cited by 183
Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition
Umemura, A., Park, E. J., Taniguchi, K., Lee, J. H., Shalapour, S., Valasek, M. A., Aghajan, M., Nakagawa, H., Seki, E., Hall, M. N., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.001 · Cited by 183
Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis
Heldin, C. ‐., Lennartsson, J., & Westermark, B. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12690 · Cited by 181
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
Gao, L., Wang, X., Tang, Y., Huang, S., Hu, C.-A. A., & Teng, Y. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0478-9 · Cited by 179
Dai, H., Tong, C., Shi, D., Chen, M., Guo, Y., Chen, D., Han, X., Wang, H., Wang, Y., & Shen, P. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1846926 · Cited by 179
Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis
Brar, G., Greten, T. F., Graubard, B. I., McNeel, T. S., Petrick, J. L., McGlynn, K. A., & Altekruse, S. F. (2020) · Hepatology Communications · doi:10.1002/hep4.1564 · Cited by 178
Ezzoukhry, Z., Louandre, C., Trécherel, E., Godin, C., Chauffert, B., Dupont, S., Diouf, M., Barbare, J., Mazière, J., & Galmiche, A. (2012) · International Journal of Cancer · doi:10.1002/ijc.27604 · Cited by 177
Heldin, C.-H., & Lennartsson, J. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009100 · Cited by 176
Liu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K.-W., Sun, H., Zeng, X., Tang, W., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317257 · Cited by 176
Self-citationFeng, Z., Li, H., Liu, Q., Duan, J., Zhou, W., Yu, X., Chen, Q., Liu, Z., Wang, W., & Rong, P. (2023) · Radiology · doi:10.1148/radiol.221291 · Cited by 175
Transcriptional mechanisms of WNT5A based on NF-κB, Hedgehog, TGFβ, and Notch signaling cascades
Katoh (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000190 · Cited by 174
JAK/STAT signaling in hepatocellular carcinoma
Tang, J. J. H., Thng, D. K. H., Lim, J. J., & Toh, T. B. (2020) · Hepatic Oncology · doi:10.2217/hep-2020-0001 · Cited by 173
Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6804 · Cited by 172
Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer
Jeong, S.-H., Kim, H.-B., Kim, M.-C., Lee, J.-M., Lee, J. H., Kim, J.-H., Kim, J.-W., Park, W.-Y., Kim, S.-Y., Kim, J. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95802 · Cited by 172
Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis
Shen, H.-M., & Ong, C.-N. (1996) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/s0165-1110(96)90005-6 · Cited by 171
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
Cervello, M., McCubrey, J. A., Cusimano, A., Lampiasi, N., Azzolina, A., & Montalto, G. (2012) · Oncotarget · doi:10.18632/oncotarget.466 · Cited by 170
TGF-β, EMT, and resistance to anti-cancer treatment
Wang, X., Eichhorn, P. J. A., & Thiery, J. P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.10.004 · Cited by 170
Aberrant Super‐Enhancer Landscape in Human Hepatocellular Carcinoma
Tsang, F. H., Law, C., Tang, T. C. C., Cheng, C. L., Chin, D. W., Tam, V., Wei, L., Wong, C. C., Ng, I. O., & Wong, C. (2019) · Hepatology · doi:10.1002/hep.30544 · Cited by 169
Yi, C., Shen, Z., Stemmer-Rachamimov, A., Dawany, N., Troutman, S., Showe, L. C., Liu, Q., Shimono, A., Sudol, M., Holmgren, L., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004060 · Cited by 168
Deregulation of Hippo kinase signalling in Human hepatic malignancies
Li, H., Wolfe, A., Septer, S., Edwards, G., Zhong, X., Bashar Abdulkarim, A., Ranganathan, S., & Apte, U. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02646.x · Cited by 168
Receptor tyrosine kinase inhibitors in cancer
Ebrahimi, N., Fardi, E., Ghaderi, H., Palizdar, S., Khorram, R., Vafadar, R., Ghanaatian, M., Rezaei‐Tazangi, F., Baziyar, P., Ahmadi, A., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04729-4 · Cited by 168
Nivolumab for the treatment of hepatocellular carcinoma
Finkelmeier, F., Waidmann, O., & Trojan, J. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1535315 · Cited by 167
Philips, G. M., Chan, I. S., Swiderska, M., Schroder, V. T., Guy, C., Karaca, G. F., Moylan, C., Venkatraman, T., Feuerlein, S., Syn, W.-K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023943 · Cited by 165
Signaling pathways in hepatocellular carcinoma
(2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.10.002 · Cited by 165
Hedgehog signalling in liver pathophysiology
Machado, M. V., & Diehl, A. M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.017 · Cited by 164
Non-Canonical Notch Signaling in Cancer and Immunity
Ayaz, F., & Osborne, B. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00345 · Cited by 163
Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma
Zhang, W., He, H., Zang, M., Wu, Q., Zhao, H., Lu, L.-L., Ma, P., Zheng, H., Wang, N., Zhang, Y., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.024 · Cited by 163
Self-citationWei, L., Chiu, D. K.-C., Tsang, F. H.-C., Law, C.-T., Cheng, C. L.-H., Au, S. L.-K., Lee, J. M.-F., Wong, C. C.-L., Ng, I. O.-L., & Wong, C.-M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.015 · Cited by 163
Vasan, N., & Cantley, L. C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00633-1 · Cited by 163
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Joshi, J. J., Coffey, H., Corcoran, E., Tsai, J. J.-Y., Huang, C. L., Ichikawa, K., Prajapati, S., Hao, M., Bailey, S. L., Wu, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1865 · Cited by 162
Tan, D. J. H., Setiawan, V. W., Ng, C. H., Lim, W. H., Muthiah, M. D., Tan, E. X. X., Dan, Y. Y., Roberts, L. R., Loomba, R. S., & Huang, D. Q. (2022) · Hepatology · doi:10.1002/hep.32758 · Cited by 162
High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT
Bu, L., Zhang, Z., Chen, J., Fan, Y., Guo, J., Su, Y., Wang, H., Zhang, X., Wu, X., Jiang, Q., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-330826 · Cited by 162
Self-citationHepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma
Kim, W., Khan, S. K., Liu, Y., Xu, R., Park, O., He, Y., Cha, B., Gao, B., & Yang, Y. (2018) · Gut · doi:10.1136/gutjnl-2017-314061 · Cited by 160
The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
Wang, H., Rao, B., Lou, J., Li, J., Liu, Z., Li, A., Cui, G., Ren, Z., & Yu, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00055 · Cited by 160
Mohan, C. D., Bharathkumar, H., Bulusu, K. C., Pandey, V., Rangappa, S., Fuchs, J. E., Shanmugam, M. K., Dai, X., Li, F., Deivasigamani, A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.601104 · Cited by 159
Hedgehog Signaling Pathway Regulates Autophagy in Human Hepatocellular Carcinoma Cells
Wang, Y., Han, C. L., Lu, L., Magliato, S. A., & Wu, T. (2013) · Hepatology · doi:10.1002/hep.26394 · Cited by 159
Detecting Liver Cancer Using Cell-Free DNA Fragmentomes
Foda, Z. H., Annapragada, A. V., Boyapati, K., Bruhm, D. C., Vulpescu, N. A., Medina, J. E., Mathios, D., Cristiano, S., Niknafs, N., Luu, H. T., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0659 · Cited by 159
Adebayo Michael, A. O., Ko, S., Tao, J., Moghe, A., Yang, H., Xu, M., Russell, J. O., Pradhan-Sundd, T., Liu, S., Singh, S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.002 · Cited by 155
STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma
Lee, C., & Cheung, S. (2019) · Cancers · doi:10.3390/cancers11111646 · Cited by 155
The Role of TP53 in Adaptation and Evolution
Voskarides, K., & Giannopoulou, N. (2023) · Cells · doi:10.3390/cells12030512 · Cited by 155
Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome
Zoulim, F., Chen, P., Dandri, M., Kennedy, P. T. F., & Seeger, C. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.037 · Cited by 153
Pan, Y., & Wang, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608599200 · Cited by 152
Toh, T. B., Lim, J. J., Hooi, L., Rashid, M. B. M. A., & Chow, E. K. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.035 · Cited by 152
Djojosubroto, M. W., Chin, A. C., Go, N., Schaetzlein, S., Manns, M. P., Gryaznov, S., Harley, C. B., & Rudolph, L. K. (2005) · Hepatology · doi:10.1002/hep.20822 · Cited by 151
Bitzer, M., Horger, M., Giannini, E. G., Ganten, T. M., Wörns, M., Siveke, J. T., Dollinger, M., Gerken, G., Scheulen, M. E., Wege, H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.043 · Cited by 151
Chen, J., Zaidi, S., Rao, S., Chen, J., Phan, L. M., Farci, P., Su, X., Shetty, K., White, J. C., Zamboni, F., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.09.007 · Cited by 151
Self-citationTargeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Kudo, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i7.789 · Cited by 149
Deep whole-genome analysis of 494 hepatocellular carcinomas
Chen, L., Zhang, C., Xue, R., Liu, M., Bai, J., Bao, J., Wang, Y., Jiang, N., Li, Z., Wang, W., et al. (2024) · Nature · doi:10.1038/s41586-024-07054-3 · Cited by 148
Wei, W., Chua, M., Grepper, S., & So, S. K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24810 · Cited by 146
Yu, B., Yang, X., Xu, Y., Yao, G., Shu, H., Lin, B., Hood, L., Wang, H., Yang, S., Gu, J., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.11.020 · Cited by 143
Self-citationMETTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma
Wang, L., Yang, Q., Zhou, Q., Fang, F., Lei, K., Liu, Z., Zheng, G., Zhu, L., Huo, J., Li, X., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216122 · Cited by 143
Llópiz, D., Ruiz, M., Villanueva, L., Iglesias, T., Silva, L., Egea, J., Lasarte, J. J., Pivette, P., Trochon-Joseph, V., Vasseur, B., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2283-0 · Cited by 141
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
Huynh, H. T., Chow, P. K. H., Soo, K. C., Toh, H. C., Choo, S. P., Foo, K. F., Poon, D. Y. H., Ngo, V. C., & Tran, E. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00364.x · Cited by 140
Yamada, S., Takashina, Y., 渡辺, 光., Nagamine, R., Saito, Y., Kamada, N., & Saito, H. (2018) · Oncotarget · doi:10.18632/oncotarget.24066 · Cited by 140
Wainberg, Z. A., Segal, N. H., Jaeger, D., Lee, K.-H., Marshall, J. L., Antonia, S. J., Butler, M. O., Sanborn, R. E., Nemunaitis, J. J., Carlson, C. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4071 · Cited by 140
Leung, H.-W., Leung, C. O. N., Lau, E. Y.-T., Chung, K. P. S., Mok, E. H. K., Lei, M. M. L., Leung, R. W. H., Tong, M., Keng, V. W., Ma, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0184 · Cited by 140
Tao, J., Xu, E., Zhao, Y., Singh, S., Li, X., Couchy, G., Chen, X., Zucman‐Rossi, J., Chikina, M. D., & Monga, S. P. (2016) · Hepatology · doi:10.1002/hep.28601 · Cited by 139
Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma
Fu, Y., Urban, D. J., Nani, R. R., Zhang, Y., Li, N., Fu, H., Shah, H., Gorka, A. P., Guha, R., Chen, L., et al. (2018) · Hepatology · doi:10.1002/hep.30326 · Cited by 139
Moore, G., Annett, S., McClements, L., & Robson, T. (2020) · Cells · doi:10.3390/cells9061503 · Cited by 137
AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma
Zhu, Q., Ma, Y., Liang, J., Wei, Z., Li, M., Zhang, Y., Liu, M., He, H., Qu, C., Cai, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00713-1 · Cited by 137
NUAK2 is a critical YAP target in liver cancer
Yuan, W.-C., Pepe-Mooney, B. J., Galli, G. G., Dill, M. T., Huang, H., Hao, M., Wang, Y., Liang, H., Calogero, R., & Camargo, F. D. (2018) · Nature Communications · doi:10.1038/s41467-018-07394-5 · Cited by 135
Notch-1 associates with IKKα and regulates IKK activity in cervical cancer cells
Song, L., Peng, Y., Yun, J., Rizzo, P., Chaturvedi, V., Weijzen, S., Kast, W. M., Stone, P. J. B., Santos, L., Loredo, Á., et al. (2008) · Oncogene · doi:10.1038/onc.2008.190 · Cited by 134
Liu, R., Li, Y., Tian, L., Shi, H., Wang, J., Liang, Y., Sun, B., Wang, S., Zhou, M., Wu, L., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.030 · Cited by 133
Self-citationDrug Screening Identifies Niclosamide as an Inhibitor of Breast Cancer Stem-Like Cells
Wang, Y.-C., Chao, T., Chang, C., Yo, Y.-T., Yu, M.-H., & Lai, H.-C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074538 · Cited by 132
The Hedgehog pathway: role in cell differentiation, polarity and proliferation
Jia, Y., Wang, Y., & Xie, J. (2015) · Archives of Toxicology · doi:10.1007/s00204-014-1433-1 · Cited by 132
Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451
Roberts, W. G., Whalen, P. M., Söderström, E., Moraski, G. C., Lyssikatos, J. P., Wang, H. F., Cooper, B. A., Baker, D. A., Savage, D. M., Dalvie, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.957.65.3 · Cited by 132
Li, B., Yan, C., Zhu, J., Chen, X., Fu, Q., Zhang, H., Tong, Z., Liu, L., Zheng, Y., Zhao, P., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01037 · Cited by 132
Shi, W., Dai, M., Zhang, C., Teng, K., Wang, F., Li, H., Sun, W., Feng, Z., Kang, T., Guan, X., et al. (2020) · Protein & Cell · doi:10.1007/s13238-020-00766-y · Cited by 131
Ningarhari, M., Caruso, S., Hirsch, T. Z., Bayard, Q., Franconi, A., Védié, A., Noblet, B., Blanc, J., Amaddeo, G., Ganne‐Carrié, N., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.052 · Cited by 131
Bárcena‐Varela, M., Caruso, S., Llerena, S., Álvarez‐Sola, G., Uriarte, I., Latasa, M. U., Urtasun, R., Rebouissou, S., Alvarez, L., Jimenez, M., et al. (2019) · Hepatology · doi:10.1002/hep.30168 · Cited by 130
Liu, J., Ma, Q., Zhang, M., Wang, X., Zhang, D., Li, W., Wang, F., & Wu, E. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.001 · Cited by 130
Ye, T., Xiong, Y., Yan, Y., Xia, Y., Song, X., Liu, L., Li, D., Wang, N., Zhang, L., Zhu, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085887 · Cited by 130
Xia, H., Dai, X., Yu, H., Zhou, S., Fan, Z., Wei, G., Tang, Q., Gong, Q., & Bi, F. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0302-x · Cited by 129
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Oh, D., Lee, S., Han, S., Kim, M., Kim, T.-M., Kim, T., Heo, D. S., Yuasa, M., Yanagihara, Y., & Bang, Y. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.249 · Cited by 128
Sohn, B. H., Shim, J., Kim, S.-B., Jang, K. Y., Kim, S. M., Kim, J. H., Hwang, J., Jang, H.-J., Lee, H., Kim, S.-C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1447 · Cited by 127
Lu, X., Paliogiannis, P., Calvisi, D. F., & Chen, X. (2020) · Hepatology · doi:10.1002/hep.31310 · Cited by 127
Pathil, A., Armeanu, S., Venturelli, S., Mascagni, P., Weiß, T. S., Gregor, M., Lauer, U. M., & Bitzer, M. (2006) · Hepatology · doi:10.1002/hep.21054 · Cited by 126
Yeo, W., Chan, S. L., Mo, F. K., Chu, C. M., Hui, J. W., Tong, J. H., Chan, A. W., Koh, J., Hui, E. P., Loong, H., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1334-6 · Cited by 125
Chung, S. I., Moon, H., Ju, H.-L., Cho, K. J., Kim, D. Y., Han, K., Eun, J. W., Nam, S. W., Ribback, S., Dombrowski, F., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.007 · Cited by 124
Shah, A., Bloomquist, E. W., Tang, S. W., Fu, W., Bi, Y., Liu, Q., Yu, J., Zhao, P., Palmby, T. R., Goldberg, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2369 · Cited by 123
Yuan, X., Wu, H. K., Xu, H., Han, N., Chu, Q., Yu, S., Chen, Y., & Wu, K. (2015) · Scientific Reports · doi:10.1038/srep10338 · Cited by 122
Kim, Y., Yoon, J. W., Xiao, X., Dean, N. M., Monia, B. P., & Marcusson, E. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3040 · Cited by 122
Differential repetitive DNA methylation in multiple myeloma molecular subgroups
Bollati, V., Fabris, S., Pegoraro, V., Ronchetti, D., Mosca, L., Deliliers, G. L., Motta, V., Bertazzi, P. A., Baccarelli, A., & Neri, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp149 · Cited by 122
Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms
Wang, Q., Yu, W.-N., Chen, X., Peng, X.-D., Jeon, S., Birnbaum, M. J., Guzman, G., & Hay, N. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.008 · Cited by 121
Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer
Stock, P., Monga, D. K., Tan, X., Micsenyi, A., Loizos, N., & Monga, S. P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0720 · Cited by 120
NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling
Gong, C., Ai, J., Fan, Y., Gao, J., Liu, W., Feng, Q., Liao, W., & Wu, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217916 · Cited by 120
Fu, R., Jiang, S., Li, J., Chen, H., & Zhang, X. (2020) · Medical Oncology · doi:10.1007/s12032-020-01350-4 · Cited by 120
Meng, F., Zhao, J., Tan, A. T., Hu, W., Wang, S., Jin, J., Wu, J., Li, Y., Shi, L., Fu, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10250-2 · Cited by 120
Self-citationLoizos, N., Xu, Y. C., Huber, J., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0114 · Cited by 118
Kim, J., Bradford, D., Larkins, E. A., Pai-Scherf, L. H., Chatterjee, S., Mishra-Kalyani, P. S., Wearne, E., Helms, W. S., Ayyoub, A., Bi, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0967 · Cited by 118
Abel, M., Sène, D., Pol, S., Bourlière, M., Poynard, T., Charlotte, F., Cacoub, P., & Caillat‐Zucman, S. (2006) · Hepatology · doi:10.1002/hep.21438 · Cited by 117
Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors
Lai, X., Stiff, A. R., Duggan, M. C., Wesolowski, R., Carson, W. E., & Friedman, A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721559115 · Cited by 116
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115
Toh, H. C., Chen, P., Carr, B. I., Knox, J. J., Gill, S., Ansell, P. J., McKeegan, E. M., Dowell, B. L., Pedersen, M., Qin, Q., et al. (2012) · Cancer · doi:10.1002/cncr.27758 · Cited by 115
Constitutive Notch2 signaling induces hepatic tumors in mice
Dill, M. T., Tornillo, L., Fritzius, T., Terracciano, L., Semela, D., Bettler, B., Heim, M. H., & Tchorz, J. S. (2012) · Hepatology · doi:10.1002/hep.26165 · Cited by 115
Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2480-2 · Cited by 115
Fan, Z., Duan, J., Wang, L., Xiao, S., Li, L., Yan, X., Yao, W. J., Wu, L., Zhang, S., Zhang, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.040 · Cited by 115
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
Chu, J., Ge, F. J., Zhang, B., Wang, Y., Silvestris, N., Liu, L. J., Zhao, C. H., Li, L., Brunetti, A. E., Fu, Y. L., et al. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-16 · Cited by 113
Maini, M. K., & Pallett, L. J. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30007-4 · Cited by 113
Bayo, J., Fiore, E. J., Domínguez, L. M., Real, A., Malvicini, M., Rizzo, M., Atorrasagasti, C., García, M. G., Argemí, J., Martínez, E. D., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.007 · Cited by 113
Wang, S., Wang, Y., Xun, X., Zhang, C., Xiao, X., Cheng, Q., Hu, S., Li, Z., & Zhu, J. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-1523-2 · Cited by 112
Self-citationReceptor tyrosine kinases: biological functions and anticancer targeted therapy
Zhang, N., & Li, Y. (2023) · MedComm · doi:10.1002/mco2.446 · Cited by 112
Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation
Chen, L., Shen, R. Z., Ye, Y., Pu, X.-A., Liu, X., Duan, W., Wen, J., Zimmerer, J., Wang, Y., Liu, Y., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000293 · Cited by 111
Differential effects of targeting Notch receptors in a mouse model of liver cancer
Huntzicker, E. G., Hötzel, K., Choy, L., Che, L., Ross, J., Pau, G., Sharma, N., Siebel, C. W., Chen, X., & French, D. M. (2014) · Hepatology · doi:10.1002/hep.27566 · Cited by 111
Diverse expression of ErbB receptor proteins during rat liver development and regeneration
Carver, R. S., Stevenson, M. C., Scheving, L. A., & Russell, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37060 · Cited by 111
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
Royce, M., Osgood, C., Mulkey, F., Bloomquist, E., Pierce, W. F., Roy, A., Kalavar, S., Ghosh, S., Philip, R., Rizvi, F., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02742 · Cited by 111
Kiely, P. A., O’Gorman, D. M., Luong, K., Dorit Ron, A., & O’Connor, R. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01868-05 · Cited by 110
Ye, Y., Zhao, J., Lu, Y., Gao, C.-C., Yang, Y., Liang, S.-Q., Lu, Y., Wang, L., Yue, S., Dou, K., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1691 · Cited by 110
Bárcena‐Varela, M., Paish, H. L., Alvarez, L., Uriarte, I., Latasa, M. U., Santamaría, E., Recalde, M., Garate, M., Clavería-Cabello, A., Colyn, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320205 · Cited by 110
Tada, M., Kanai, F., Tanaka, Y., Tateishi, K., Ohta, M., Asaoka, Y., Seto, M., Muroyama, R., Fukai, K., Imazeki, F., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1181 · Cited by 109
The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?
Gonzalez‐Sanchez, E., Vaquero, J., Fernández‐Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021) · Cancers · doi:10.3390/cancers13133248 · Cited by 109
Jühling, F., Hamdane, N., Crouchet, É., Shen, L., Saghire, H. E., Mukherji, A., Fujiwara, N., Oudot, M. A., Thumann, C., Saviano, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318918 · Cited by 108
Che, Y., Chen, G., Guo, Q., Duan, Y., Feng, H., & Xia, Q. (2023) · Hepatology · doi:10.1097/hep.0000000000000047 · Cited by 108
Self-citationLi, M., Wang, L., Cong, L., Wong, C. C., Zhang, X., Chen, H., Zeng, T., Li, B., Jia, X., Huo, J., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000591 · Cited by 107
Ma, L., Wang, X., Jia, T., Wei, W., Chua, M., & So, S. K. (2015) · Oncotarget · doi:10.18632/oncotarget.4455 · Cited by 106
Kang, Y., Yau, T. C. C., Park, J.-W., Lim, H. Y., Lee, T.-H., Obi, S., Chan, S. L., Qin, S., Kim, R. D., Casey, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv388 · Cited by 106
Lu, X., Chen, H., Patterson, A. V., Smaill, J. B., & Ding, K. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01531 · Cited by 104
Golob‐Schwarzl, N., Krassnig, S., Toeglhofer, A. M., Park, Y. N., Gogg-Kamerer, M., Vierlinger, K., Schroeder, F., Rhee, H., Schicho, R., Fickert, P., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.003 · Cited by 102
Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
Bang, J., Jun, M., Lee, S., Moon, H., & Ro, S. W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082130 · Cited by 102
Zhou, B., Yan, Z., Liu, R., Shi, P., Qian, S., Qu, X.-D., Zhu, L., Zhang, W., & Wang, J. (2016) · Radiology · doi:10.1148/radiol.2016150719 · Cited by 101
The role of MDM2–p53 axis dysfunction in the hepatocellular carcinoma transformation
Cao, H., Chen, X., Wang, Z., Wang, L., Xia, Q., & Zhang, W. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0287-y · Cited by 101
Self-citationRajapakse, J., Khatiwada, S., Akon, A. C., Yu, K. L., Shen, S., & Zekry, A. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2240031 · Cited by 101
Role of Cyclin D1 as a Mediator of c-Met– and β-Catenin–Induced Hepatocarcinogenesis
Patil, M. A., Lee, S. A., Macias, E., Lam, E. T., Xu, C., Jones, K. D., Ho, C., Rodríguez‐Puebla, M. L., & Chen, X. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2514 · Cited by 100
Corso, S., & Giordano, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0040 · Cited by 100
A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
Abou‐Alfa, G. K., Capanu, M., O'Reilly, E. M., Ma, J., Chou, J. F., Gansukh, B., Shia, J., Kalin, M. F., Katz, S. S., Abad, L. W., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.008 · Cited by 98
Tang, B., Tang, F., Wang, Z., Qi, G., Liang, X., Li, B., Yuan, S., Liu, J., Yu, S., & He, S. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0344-9 · Cited by 98
Zhang, R., Wei, D., Liu, Z.-K., Yong, Y., Wei, W., Zhang, Z., Lv, J., Zhang, Z., Chen, Z., & Bian, H. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00233 · Cited by 98
Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint
Schmidt, N. M., Wing, P. A. C., Diniz, M. O., Pallett, L. J., Swadling, L., Harris, J. M., Burton, A. R., Jeffery-Smith, A., Zakeri, N., Amin, O. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22967-7 · Cited by 98
Drugging IGF-1R in cancer: New insights and emerging opportunities
Wang, P., Mak, V. C. Y., & Cheung, L. W. T. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.03.002 · Cited by 98
Zhang, T., Sun, H., Xu, Y. Y., Zhang, K., Wang, L., Qin, L., Wu, W., Liu, Y., Ye, S., & Tang, Z. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0944 · Cited by 97
Zhao, Z., Song, J., Tang, B., Fang, S., Zhang, D., Zheng, L., Wu, F., Gao, Y., Chen, C., Hu, X., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01769-7 · Cited by 97
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors
Duke, E. S., Bradford, D., Marcovitz, M., Amatya, A. K., Mishra-Kalyani, P. S., Nguyen, E., Price, L., Zirkelbach, J. F., Li, Y., Bi, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0459 · Cited by 97
Yau, T., Kaseb, A., Cheng, A.-L., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00454-5 · Cited by 97
Tian (2009) · International Journal of Oncology · doi:10.3892/ijo_00000209 · Cited by 95
Ling, S., Song, L., Fan, N., Feng, T., Liu, L., Yang, X., Wang, M., Li, Y., Tian, Y., Zhao, F. H., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3799 · Cited by 95
The Alternatively Spliced Acid Box Region Plays a Key Role in FGF Receptor Autoinhibition
Kalinina, J., Dutta, K., Ilghari, D., Beenken, A., Goetz, R., Eliseenkova, A. V., Cowburn, D., & Mohammadi, M. (2012) · Structure · doi:10.1016/j.str.2011.10.022 · Cited by 94
Sarfstein, R., Pasmanik‐Chor, M., Yeheskel, A., Edry, L., Shomron, N., Warman, N., Wertheimer, E., Maor, S., Shochat, L., & Werner, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.281782 · Cited by 93
miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR
Ji, L., Lin, Z., Wan, Z., Xia, S., Shi, J., Cen, D., Cai, L., Xu, J., & Cai, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2413-4 · Cited by 93
Moeini, A., Torrecilla, S., Tovar, V., Montironi, C., Andreu-Oller, C., Peix, J., Higuera, M., Pfister, D., Ramadori, P., Pinyol, R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.07.028 · Cited by 92
Sun, X., Zhang, J., Hou, Z., Han, Q., Zhang, C., & Tian, Z. (2015) · Cell Cycle · doi:10.4161/15384101.2014.977112 · Cited by 92
Minireview: Were the IGF Signaling Inhibitors All Bad?
Beckwith, H. C., & Yee, D. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1157 · Cited by 91
Yu, J., Zhu, P., Shi, L., Gao, N., Li, Y., Shu, C., Xu, Y., Yu, Y., He, J., Guo, D., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.11.011 · Cited by 91
Bugide, S., Gupta, R., Green, M. R., & Wajapeyee, N. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102718118 · Cited by 90
Coactivation of AKT and β-Catenin in Mice Rapidly Induces Formation of Lipogenic Liver Tumors
Stauffer, J. K., Scarzello, A. J., Andersen, J. B., Kluyver, R. L. D., Back, T. C., Weiss, J. M., Thorgeirsson, S. S., & Wiltrout, R. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2705 · Cited by 89
Lim, H. Y., Merle, P., Weiss, K. H., Yau, T. C. C., Ross, P. J., Mazzaferro, V., Blanc, J., Ma, Y. T., Yen, C. J., Kocsis, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3588 · Cited by 88
Chen, S., & Xia, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27567 · Cited by 88
Liu, X., Lu, Y., & Qin, S. (2021) · Future Oncology · doi:10.2217/fon-2020-1290 · Cited by 88
Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts
Chiu, M., Tardito, S., Pillozzi, S., Arcangeli, A., Armento, A., Uggeri, J., Missale, G., Bianchi, M. G., Barilli, A., Dall’Asta, V., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.425 · Cited by 87
Yang, Z., Wang, D., Wang, G., Zhang, Q.-H., Liu, J.-M., Peng, P., & Liu, X. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0701-6 · Cited by 87
Damodaran, S., Zhao, F., Deming, D. A., Mitchell, E. P., Wright, J. J., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L., Patton, D. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01648 · Cited by 87
Tao, J., Zhang, R., Singh, S., Poddar, M., Xu, E., Oertel, M., Chen, X., Ganesh, S., Abrams, M. T., & Monga, S. P. (2016) · Hepatology · doi:10.1002/hep.28975 · Cited by 86
Liu, M., Wei, F., Wang, J., Yu, W., Shen, M., Liu, T., Zhang, D., Wang, Y., Ren, X., & Sun, Q. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03745-1 · Cited by 85
Sun, W., Huang, H. F., He, B., Hu, D.-H., Li, P., Yu, Y., Zhou, X., Lv, Z., Zhou, L., Hu, T., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.008 · Cited by 84
DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma
Zhang, L., Li, H., Shereda, R., Lu, Q., Weisenberger, D. J., O'Connell, C. L., Machida, K., An, W., Lenz, H., El-Khoueiry, A. B., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215899 · Cited by 84
TAZ is indispensable for c-MYC-induced hepatocarcinogenesis
Wang, H., Zhang, S., Zhang, Y., Jia, J., Wang, J., Liu, X., Zhang, J., Song, X., Ribback, S., Cigliano, A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.021 · Cited by 83
A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors
Pathania, S., Pentikäinen, O. T., & Singh, P. K. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188631 · Cited by 83
Sue, S. R., Chari, R. S., Kong, F., Mills, J. J., Fine, R. L., Jirtle, R. L., & Meyers, W. C. (1995) · Annals of Surgery · doi:10.1097/00000658-199508000-00009 · Cited by 81
Ahn, D. H., Li, J., Wei, L., Doyle, A., Marshall, J. L., Schaaf, L. J., Phelps, M. A., Villalona-Calero, M. A., & Bekaii‐Saab, T. (2015) · Scientific Reports · doi:10.1038/srep12122 · Cited by 80
Lee, J. M., Yang, J., Newell, P., Singh, S., Parwani, A. V., Friedman, S. L., Nejak‐Bowen, K. N., & Monga, S. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.020 · Cited by 79
Metadata
- Authors
- Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-02-07
- Volume
- 10
- Issue
- 1
- Pages
- 35-35
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4407203105
- Cited by
- 341
- References
- 641
- FWCI
- 165.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.